Merck KGaA Sigma-Aldrich Licenses CRISPR-Cas9 Tech to Horizon Discovery The deal enables Horizon to support gene editing researchers who need cell-line engineering beyond loss-of-function CRISPR studies into CRISPR-mediated targeted knock-in. Merck, Burning Rock Ink Liquid Biopsy Companion Diagnostics Deal The companies intend to develop Burning Rock's 168-gene OncoCompass Target test as a companion to Merck's MET inhibitor Tepmetko in mainland China. Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations. Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib. AmoyDx Strikes CDx Development Deal for Merck KGaA Cancer Drug AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan. Aug 3, 2020 Metabolon, Merck KGaA Form Metabolomics Alliance Mar 25, 2020 Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx Nov 19, 2019 Personalis, Merck KGaA to Study Cancer Biomarkers Using Immunogenomics Platform Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Oct 3, 2018 Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic Sep 10, 2018 Definiens, Merck KGaA Partner for Biomarker Discovery Jun 20, 2018 Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations Premium Jan 10, 2018 ThermaGenix, MilliporeSigma Ink PCR Reagents Distribution Deal Dec 27, 2017 HTG Expands Collaboration With Merck KGaA Nov 27, 2017 Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests Sep 26, 2017 FDA Gives Guardant Health IDE Approval for Clinical Trial of Merck KGaA Cancer Drug Jun 15, 2017 Human Longevity, Merck KGaA Form Cancer Biomarker Partnership Jun 13, 2017 MilliporeSigma's Proxy-CRISPR Tech Aims to Increase Usability of Native CRISPR Proteins Premium May 30, 2017 Lonza's New Investments in Exosome Technologies Reflect Growing Industry Interest Premium Apr 11, 2017 MilliporeSigma Developing New Instrument for Single-Molecule Biomarker Detection Premium Jan 6, 2017 Guardant Health, Pharma Firms to Develop 500-Gene Liquid Biopsy Panel Dec 1, 2016 Roche, Merck KGaA Expand PCR Distribution Agreement Nov 30, 2016 Evotec Inks Deal to Offer Merck KGaA Gene Editing, Silencing Technologies Oct 12, 2016 HTG, Merck KGaA Ink CDx Development Deal for Lymphoma Drug Jul 28, 2016 Merck KGaA, AmoyDx Partner on Colorectal Cancer Test for Chinese Market Load More Breaking News Canadian Healthcare Providers, Policymakers Value Different Aspects of Clinical Genomic Sequencing New Products Posted to GenomeWeb: Oxford Nanopore, Bio-Rad, NanoString, More People in the News at OraSure, Element Biosciences, Micronoma, More Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit In Brief This Week: SQI Diagnostics, T2 Biosystems, Enhanc3D, QuidelOrtho, More Illumina, Precision Health Research Singapore Partner for 100K Genomes Population Study The Scan Blend of Omicron With Delta The Associated Press reports that currently circulating Omicron variants have some features previously seen in the Delta variant. Limited Contrast The New York Times reports that there is a shortage of a contrast agent used for some medical scans. Pig Improvement Farmers in China are using genetics to improve their hog herds, according to Reuters. Science Papers Present Way to Molecularly Classify Prostate Cancer, Saliva-Based SARS-CoV-2 Test, More In Science this week: approach to molecularly classify prostate tumors, saliva-based test for SARS-CoV-2, and more.